Cystic fibrosis investigators within the P30 Center require access to expertise and specialized equipment fortheir studies of CFTR expression and function. For both established CF laboratories and those new to CFresearch, a need has been identified for developing new cell lines expressing mutant and wild type CFTR,and for dedicated equipment and biophysical protocols necessary to assess CFTR function. In particular, wepropose two specific aims:
Specific Aim 1. Cellular models expressing wild type and mutant CFTR will be developed and provided byCore A. These will include primary cells from murine and human lungs, novel lentiviral transduced cell lines,and innovative CF models derived by zinc finger endonuclease modification of the CFTR locus in vitro.
Specific Aim 2. Assistance, equipment and expertise necessary to perform functional assays of CFTR inthe above cell models (Aim 1) will include fluorescent (halide sensitive) dye protocols, Ussing chamberassays and biophysical techniques (patch clamp) necessary to investigate CFTR activity and regulation.The Core will aid in the development/validation of new CF cell models; provide primary murine airwayepithelial cells encoding specific CFTR mutations; and assist investigators with their experiments to test theeffects of AF508 on CFTR protein stability and channel function. Collaborative studies involvingmetabolomic consequences of mutations in CFTR, discovery of peptides from the first cytosolic loop ofCFTR that specifically block NBD1 TMD1 binding and numerous other NIH funded projects will also beassisted by the Core.Core A will foster interdisciplinary research by providing valuable new cell models and assays of CFTRexpression and function to investigators less familiar with the requisite techniques, and contribute toinnovative studies of CF pathogenesis and experimental therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
1P30DK072482-01A1
Application #
7288651
Study Section
Special Emphasis Panel (ZDK1-GRB-6 (J1))
Project Start
2007-04-01
Project End
2012-03-31
Budget Start
2007-04-01
Budget End
2008-04-30
Support Year
1
Fiscal Year
2007
Total Cost
$197,242
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Brand, Jeffrey D; Lazrak, Ahmed; Trombley, John E et al. (2018) Influenza-mediated reduction of lung epithelial ion channel activity leads to dysregulated pulmonary fluid homeostasis. JCI Insight 3:
Cho, Do-Yeon; Lim, Dong-Jin; Mackey, Calvin et al. (2018) l-Methionine anti-biofilm activity against Pseudomonas aeruginosa is enhanced by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor. Int Forum Allergy Rhinol 8:577-583
Guimbellot, Jennifer S; Acosta, Edward P; Rowe, Steven M (2018) Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol 53:E6-E8
Solomon, George M; Bronsveld, Inez; Hayes, Kathryn et al. (2018) Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD). J Vis Exp :
Reeves, Emer P; O'Dwyer, Ciara A; Dunlea, Danielle M et al. (2018) Ataluren, a New Therapeutic for Alpha-1 Antitrypsin-Deficient Individuals with Nonsense Mutations. Am J Respir Crit Care Med 198:1099-1102
McCormick, Lydia L; Phillips, Scott E; Kaza, Niroop et al. (2018) Maternal Smoking Induces Acquired CFTR Dysfunction in Neonatal Rats. Am J Respir Crit Care Med 198:672-674
Duncan, Gregg A; Kim, Namho; Colon-Cortes, Yanerys et al. (2018) An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy. Mol Ther Methods Clin Dev 9:296-304
Gelfond, Daniel; Heltshe, Sonya L; Skalland, Michelle et al. (2018) Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening. J Pediatr Gastroenterol Nutr 66:657-663
Birket, Susan E; Davis, Joy M; Fernandez, Courtney M et al. (2018) Development of an airway mucus defect in the cystic fibrosis rat. JCI Insight 3:
Shei, Ren-Jay; Peabody, Jacelyn E; Kaza, Niroop et al. (2018) The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis. Curr Opin Pharmacol 43:152-165

Showing the most recent 10 out of 175 publications